Showing results (1181-1190 of 1,842) with videos related to
Sort By:
Pageof 185
Journal of Managed Care & Specialty Pharmacy|January 31, 2022
Valuing treatment in oncology: embracing a broader notion of valueSachin Kamal-Bahl, Justin Puckett, Amitabh Singh, et al.Journal of Managed Care & Specialty Pharmacy|April 22, 2022
Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)Anna Ambrosini, Emad Estemalik, Julio Pascual, et al.Journal of Managed Care & Specialty Pharmacy|April 26, 2022
The cost impact of disease progression to metastatic castration-sensitive prostate cancerQuoc-Dien Trinh, Leonardo Passos Chaves, Qi Feng, et al.Journal of Managed Care & Specialty Pharmacy|April 26, 2022
The effectiveness and value of tezepelumab for severe asthmaDavid M Rind, R Brett McQueen, Serina Herron-Smith, et al.Journal of Managed Care & Specialty Pharmacy|April 1, 2022
The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcomaKangho Suh, Josh J Carlson, Fang Xia, et al.Journal of Managed Care & Specialty Pharmacy|June 25, 2019
Value-Based Insurance Design: Current Evidence and Future DirectionsKai YeungJournal of Managed Care & Specialty Pharmacy|June 25, 2019
Are the Benefits of Value-Based Insurance Design Conclusive?Joel F FarleyJournal of Managed Care & Specialty Pharmacy|June 25, 2019
The Real-World Medicare Costs of Alzheimer Disease: Considerations for Policy and CareBruce Pyenson, Tia Goss Sawhney, Charles Steffens, et al.Journal of Managed Care & Specialty Pharmacy|May 14, 2019
Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug SpendingDiana Brixner, David T Rubin, Philip Mease, et al.Journal of Managed Care & Specialty Pharmacy|October 1, 2021
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trialsAditi A Kharat, Richard Nelson, Trang Au, et al.Pageof 185